Browse the evidence

Glucagon-like peptide-1 (GLP-1) receptor agonists are widely prescribed for the treatment of type 2 diabetes and obesity.

Practitioners should consider GLP-1 receptor agonists for managing type 2 diabetes and obesity.

A statistically lower proportion of patients in the compounded Semaglutide group (71.61%) reported at least one side effect compared to the pure Semaglutide group (77.40%).

Practitioners may consider that compounded Semaglutide is associated with a lower incidence of side effects.

The proposed nanocomplex is a promising system for long-acting injectable delivery of semaglutide, potentially enhancing patient compliance.

This delivery system may improve treatment adherence in patients requiring semaglutide.

GLP-1 RA initiation was associated with a reduced incidence rate of alcohol use disorders (AUD) post RYGB (1.1% vs. 1.8%) with a hazard ratio of 0.77.

Practitioners may consider GLP-1 RAs as a strategy to reduce AUD in patients post RYGB.

GLP-1 receptor agonists (GLP-1 RAs) can lead to modest yet statistically significant reductions in systolic blood pressure (SBP).

GLP-1 RAs may be considered as adjunctive therapies for managing hypertension.

Obesity increases the risk of hypertension and other cardiometabolic comorbidities.

Practitioners should be aware of the increased risk of hypertension in obese patients.

The evolution of anti-obesity pharmacotherapy has progressed to modern gut hormone-based therapies, notably glucagon-like peptide-1 receptor agonists (GLP-1RAs), which effectively suppress appetite and improve glycemic control.

Practitioners should consider GLP-1RAs as effective options for appetite control and glycemic management in obesity treatment.

HbA1c decreased from 5.5 ± 0.3 at baseline to 5.3 ± 0.3 at 12 weeks and to 5.2 ± 0.027 at 24 weeks.

Practitioners can expect improvements in glycemic control in patients using compounded GLP-1 ± GIP agonists.

Multiple incretin pharmaceutical agents show promise in the prevention and treatment of T2D.

Stay informed about new incretin agents for T2D prevention and treatment.

Abdominoplasty following GLP-1 RA-induced massive weight loss shows a trend toward a lower overall complication rate (20% vs 40%) compared to postbariatric surgery.

Practitioners may consider GLP-1 RA therapy as a safer option for patients seeking abdominoplasty after significant weight loss.

Leptin levels significantly decline following semaglutide treatment, particularly in the obesity group (-5.10 ng/mL).

Semaglutide may help lower leptin levels, which could be beneficial for weight management in diabetic patients.

Adiponectin levels increase significantly post-semaglutide add-on therapy, with the greatest increase in the obesity group (+3.70 μg/mL).

Increased adiponectin levels with semaglutide may enhance metabolic health in diabetic patients.

Long-term mortality was significantly lower in the GLP-1 group (odds ratio 0.58, 95% CI 0.36-0.94).

GLP-1 receptor agonists may improve long-term survival in patients undergoing endovascular treatment for aneurysms.

Obesity is associated with menstrual irregularities, poorer reproductive and obstetric outcomes, and an increased risk of endometrial cancer.

Clinicians should be aware of the reproductive health risks associated with obesity in women.

Both doses of tirzepatide (10 mg and 15 mg) showed significantly greater reductions in predicted diabetes risk compared to placebo.

Practitioners may consider the effectiveness of tirzepatide over placebo in reducing diabetes risk.

Effective weight loss, even when accompanied by gastrointestinal side effects, was associated with a greater willingness to continue Ozempic treatment.

Practitioners should emphasize the importance of weight loss effectiveness in encouraging patients to continue treatment despite side effects.

Semaglutide offers robust cardiovascular protection.

Clinicians can consider semaglutide for patients needing cardiovascular protection in obesity management.

GLP-1RAs appear to be safe and effective in patients with inflammatory bowel disease (IBD).

Healthcare providers can consider GLP-1RAs as a treatment option for IBD patients.

GLP-1RA users demonstrated significantly reduced pseudarthrosis rates at all time points: 6 months (8% vs. 12%; OR=0.702), 12 months (OR=0.730), and 24 months postoperatively (OR=0.788).

GLP-1RAs may be beneficial in reducing complications like pseudarthrosis in ACDF patients.

Semaglutide significantly reduced the risk of major limb events (LEs) compared with control interventions, with an odds ratio of 0.70 (95% CI 0.60–0.82; P < 0.0001).

Semaglutide may be an effective treatment option for reducing the risk of PAD-related complications in patients with diabetes or obesity.

The protective effect of semaglutide on limb events was consistent across patient subgroups, including those with diabetes and obesity.

Semaglutide can be considered for diverse populations at risk of PAD.

Treatment with tesamorelin led to marked reductions in waist circumference and improved lipid levels in a patient with nonobese visceral adiposity.

Tesamorelin may be an effective treatment for reducing visceral fat in specific HIV patients.

Glucagon-like peptide (GLP-1) receptor agonists may induce generalized weight loss but may not effectively target visceral abdominal fat.

GLP-1 receptor agonists may not be the best choice for targeting visceral fat in HIV patients.

1-year treatment persistence among individuals without diabetes initiating high-potency, weight loss-indicated GLP-1RA products increased from 33.2% in 2021 to 60.9% in 1H 2024.

Practitioners should note the significant improvement in treatment persistence, which may indicate better patient adherence and management strategies.